Show simple item record

dc.contributor.authorMatutes, E
dc.date.accessioned2018-07-10T10:34:44Z
dc.date.issued2012-02
dc.identifierhttp://publications.icr.ac.uk/11373/
dc.identifier.citationAMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (2), pp. 296 - 304
dc.identifier.issn0147-5185
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2012
dc.description.abstractBone marrow involvement by lymphoma is considered a systemic dissemination of the disease arising elsewhere, although some tumors may arise primarily in the bone marrow microenvironment. Primary bone marrow lymphoma (PBML) is a rare entity whose real boundaries and clinicobiological significance are not well defined. Criteria to diagnose PBML encompass isolated bone marrow infiltration, with no evidence of nodal or extranodal involvement, including the bone, and the exclusion of leukemia/lymphomas that are considered to primarily involve the bone marrow. Twenty-one out of 40 lymphomas retrospectively reviewed by the International Extranodal Lymphoma Study Group from 12 institutions in 7 different countries over a 25-year period fulfilled the inclusion criteria. These cases comprised 4 follicular lymphomas (FLs), 15 diffuse large B-cell lymphomas (DLBCLs), and 2 peripheral T-cell lymphomas, not otherwise specified. The FL cases showed paratrabecular infiltration, BCL2 protein and CD10 expression, and BCL2 gene rearrangement. DLBCL showed nodular infiltration in 6 cases and was diffuse in 9 cases; it also showed positivity for BCL2 protein (9/10) and IRF4 (6/8). Median age was 65 years with male predominance. All but 3 FL patients were symptomatic. Most cases presented with cytopenias and high lactate dehydrogenase. Four patients (3 FL cases and 1 DLBCL case) had leukemic involvement. Most DLBCL patients received CHOP-like or R-CHOP-like regimens. The outcome was unfavorable, with a median overall survival of 1.8 years. In conclusion, PBML is a very uncommon lymphoma with particular clinical features and heterogenous histology. Its recognition is important to establish accurate diagnosis and adequate therapy.
dc.format.extent296 - 304
dc.languageeng
dc.language.isoeng
dc.subjectbone marrow B-NHL diffuse large B-cell lymphoma follicular lymphoma peripheral T-cell lymphoma bone lymphoma aggressive non-Hodgkin lymphoma extranodal lymphoma b-cell lymphoma involvement concordant profile impact
dc.titlePrimary Bone Marrow Lymphoma: An Uncommon Extranodal Presentation of Aggressive Non-Hodgkin Lymphomas
dc.typeJournal Article
rioxxterms.licenseref.startdate2012-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfAMERICAN JOURNAL OF SURGICAL PATHOLOGY
pubs.issue2
pubs.notesISI Document Delivery No.: 879GD Times Cited: 0 Cited Reference Count: 27 Martinez, Antonio Ponzoni, Maurilio Agostinelli, Claudio Hebeda, Konnie M. Matutes, Estella Peccatori, Jacopo Campidelli, Cristina Espinet, Blanca Perea, Granada Acevedo, Agustin Mehrjardi, Ali Zare Martinez-Bernal, Monica Gelemur, Marta Zucca, Emanuele Pileri, Stefano Campo, Elias Lopez-Guillermo, Armando Rozman, Maria Spanish Ministry of Science and innovation[SAF 2008 03630-O]; Instituto de Salud Carlos III Red Tematica de Investigacion Cooperativa en Cancer RTICC[U.2006-RET2039-O]; Fondo de Investigaciones Sanitarias FIS[PI07-0409, PI08-0095]; Oncosuisse grant OCS[02062-03-2007] This work was supported by a Grant from the Spanish Ministry of Science and innovation SAF 2008 03630-O (E.C.), and by the Instituto de Salud Carlos III Red Tematica de Investigacion Cooperativa en Cancer RTICC U.2006-RET2039-O (E.C.), Fondo de Investigaciones Sanitarias FIS PI07-0409 (A.L.), PI08-0095 (A.M.), and the Oncosuisse grant OCS 02062-03-2007 (E.Z.). For the remaining authors none were declared. Lippincott williams & wilkins Philadelphia
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.volume36
pubs.embargo.termsNot known
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorMatutes, Estellaen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record